These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38758345)

  • 1. Correction: Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States.
    Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
    J Patient Rep Outcomes; 2024 May; 8(1):51. PubMed ID: 38758345
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States.
    Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
    J Patient Rep Outcomes; 2023 Nov; 7(1):122. PubMed ID: 38015301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.
    Farber RH; Stull DE; Witherspoon B; Evans CJ; Yonan C; Bron M; Dhanda R; Jen E; Brien CO'
    J Patient Rep Outcomes; 2024 Jan; 8(1):2. PubMed ID: 38175450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States.
    Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
    J Clin Psychiatry; 2023 Apr; 84(3):. PubMed ID: 37022752
    [No Abstract]   [Full Text] [Related]  

  • 5. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study.
    Cutler AJ; Caroff SN; Tanner CM; Shalhoub H; Lenderking WR; Pagé V; Franey E; Yonan C
    J Am Psychiatr Nurses Assoc; 2023; 29(5):389-399. PubMed ID: 34154444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
    Müller T
    Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perspective of tardive dyskinesia: results from a social media listening study.
    Farrar M; Lundt L; Franey E; Yonan C
    BMC Psychiatry; 2021 Feb; 21(1):94. PubMed ID: 33588795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMHC practices related to tardive dyskinesia screening and informed consent for neuroleptic drugs.
    Benjamin S; Munetz MR
    Hosp Community Psychiatry; 1994 Apr; 45(4):343-6. PubMed ID: 7912689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors in the development of severe forms of tardive dyskinesia.
    Yassa R; Nair NP; Iskander H; Schwartz G
    Am J Psychiatry; 1990 Sep; 147(9):1156-63. PubMed ID: 1974745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia: treatment with aripiprazole.
    Kang NR; Kim MD
    Clin Psychopharmacol Neurosci; 2011 Apr; 9(1):1-8. PubMed ID: 23430384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of severe and mild tardive dyskinesia: implications for etiology.
    Gardos G; Cole JO; Schniebolk S; Salomon M
    J Clin Psychiatry; 1987 Sep; 48(9):359-62. PubMed ID: 2887550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin E in the treatment of tardive dyskinesia: a meta-analysis.
    Xu H; Qin H; Chen S; Guan M
    Int Clin Psychopharmacol; 2022 Mar; 37(2):60-66. PubMed ID: 35045531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing antipsychotic-induced tardive dyskinesia.
    Gardos G
    Drug Saf; 1999 Feb; 20(2):187-93. PubMed ID: 10082074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive functions in tardive dyskinesia.
    Wolf ME; Ryan JJ; Mosnaim AD
    Psychol Med; 1983 Aug; 13(3):671-4. PubMed ID: 6137851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of clozapine and clonazepam co-administration in the treatment of a severe tardive dyskinesia: A case report.
    Haile K; Umer H
    SAGE Open Med Case Rep; 2019; 7():2050313X19833254. PubMed ID: 30834119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
    Souza RP; Remington G; Meltzer HY; Lieberman JA; Kennedy JL; Wong AH
    Int Clin Psychopharmacol; 2010 Sep; 25(5):264-9. PubMed ID: 20436352
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.